Biocon, Mylan launch hormone biosimilar in Australia

Biotechnology major Biocon, and company Mylan N V  announced the launch of their hormone biosimilar for the treatment of the polygenic disorder, in Australia.

“We are extraordinarily excited to alter reasonable access to Semglee, a high-quality biosimilar hormone glargine, co-developed and made by Biocon Biologics, to folks with the polygenic disorder in Australia, said the contact. There is a tendency to square measure co....